DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
| Revenue (TTM) | $14.01B |
| Gross Profit (TTM) | $4.53B |
| EBITDA | $2.83B |
| Operating Margin | 16.10% |
| Return on Equity | 88.50% |
| Return on Assets | 7.52% |
| Revenue/Share (TTM) | $204.69 |
| Book Value | $-11.96 |
| Price-to-Book | 21.63 |
| Price-to-Sales (TTM) | 0.81 |
| EV/Revenue | 1.728 |
| EV/EBITDA | 8.73 |
| Quarterly Earnings Growth (YoY) | 55.80% |
| Quarterly Revenue Growth (YoY) | 5.20% |
| Shares Outstanding | $63.80M |
| Float | $33.94M |
| % Insiders | 46.91% |
| % Institutions | 49.36% |
Volatility is currently expanding
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.
DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.
DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.
DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results," said Javier Rodriguez, CEO of DaVita Inc. "As we look to the rest of the year, we maintain our strategic focus on exciting new innovations in kidney dialysis to enhance the lives of our patients.
DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.
DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.
DENVER, July 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.
DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DVA and any ticker you trade — then tracks every position and per-strategy win rate.
